Kornimate/medical-research-clean huggingface dataset:
predictors of one-year mortality after curative surgery in patients aged 80 years or older with non-metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: the aim of this study is to determine which preoperative factors are associated with one-year postoperative mortality in patients aged ≥80 years undergoing curative surgery and compare outcomes between patients with or without risk factors.

colorectal cancer is common among older adults, and with the aging global population, the number of elderly individuals diagnosed with this condition continues to rise. current treatment guidelines identify surgery as the primary approach for managing non-metastatic colorectal cancer. previous studies have shown that factors like advanced age, frailty, comorbidities, and nutritional status can predict surgical outcomes. however, in patients over 80 years old with non-metastatic colorectal cancer, questions remain regarding the definition of advanced age and frailty, the applicability of existing assessment tools to this specific group, and the determination of optimal cut-off values, all of which require further validation. furthermore, there is a shortage of effective outpatient screening tools to identify vulnerable patients and provide reliable guidance for predicting postoperative survival. therefore, the aim of this study is to determine which preoperative factors are associated with one-year postoperative mortality in patients aged ≥80 years undergoing curative surgery and compare outcomes between patients with or without risk factors.

Eligibility criteria:
inclusion criteria: patients aged ≥80 years with stages i-iii colorectal cancer who underwent tumor resection from january 2014 to january 2019 exclusion criteria: patients undergoing procedure without colectomy, or tumor excised by transanal method were excluded from this study

Keywords: colorectal cancer geriatrics
a phase 2 study of farnesyl transferase inhibitor (r115777, tipifarnib) in patients with refractory or relapsed acute myeloid leukemia.

Conditions: Leukemia, Nonlymphocytic, Acute

Summary: the purpose of this study is to evaluate the effectiveness (response rate) and safety of tipifarnib in patients with refractory or relapsed aml.

acute myeloid leukemia (aml) accounts for approximately 25% of all cases of leukemia diagnosed in the western hemisphere. first-line chemotherapy regimens induce complete remissions in 55-75% of patients. however, between 50% and 70% of patients who achieve remission will relapse. current therapy for patients refractory to initial therapy or who relapse within 6 months of remission is unsatisfactory because complete remission rates are low and remission duration is brief. new drugs with novel mechanisms of action may be more beneficial than the currently available ones. tipifarnib represents a new class of oncology drugs which have a specific cellular target (inhibition of the farnesyl transferase protein), one of the components of the ras oncogene, as its specific mechanism of acton. it is believed that inhibition of this protein will lead to a decrease of cellular proliferation or cell death. this is an open-label, multicenter, non-comparative phase 2 study investigating the efficacy and safety of farnesyl transferase inhibition with tipifarnib administered orally as a single agent, twice daily, for the first 21 days of every 28 day cycle. patients are enrolled by disease status into two cohorts; cohort 1 includes patients with relapsed aml and cohort 2, patients with refractory aml. all patients will be treated for a sufficient length of time to determine response to study medication (effectiveness) by evaluating the rate of complete remission (cr) or complete remission with incomplete platelet recovery (crp), duration of complete remission, time to disease progression and progression-free survival, overall survival, and to characterize clinical benefit and quality of life (qol). the safety profile of tipifarnib will also be determined in patients with refractory of relapsed aml.. the patients will receive six tablets (100 mg each) of tipifarnib twice daily for 21 of 28 day cycles (7 day rest period between cycles). patients may receive tipifarnib until disease progression or unacceptable toxicity occurs.

Eligibility criteria:
inclusion criteria: * refractory or relapsed acute myeloid leukemia (aml) * eastern cooperative oncology group (ecog) performance of 0-2 * any value of wbc * able to eat food and medication orally * females must use contraception and not be pregnant exclusion criteria: * .not in another study with an investigational agent within 3 weeks of tipifarnib administration * must not have active cns leukemia * must not have disseminated intravascular coagulation (dic) disorder with evidence of hemorrhage * must not be allergic to imidazole drugs such as ketoconazole, miconazole, econazole, or terconazole.

Keywords: farnesyl transferase inhibitor relapsed or refractory acute myeloid leukemia
safety and clinical activity of thiscart22 in patients with r/r non-hodgkin's b cell lymphoma

Conditions: B-cell Malignancy

Summary: a single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of thiscart22 (allogeneic car-t targeting cd22) in patients with relapsed and/or refractory non-hodgkin's b cell lymphoma (r/r b-nhl).

thiscart22 cell is a non-gene-editing allogeneic car-t cell targeting cd22. this study is designed to evaluate the safety and clinical activity of thiscart22 in patients with cd22 positive, relapsed and/or refractory non-hodgkin's b cell lymphoma (r/r b-nhl).

Eligibility criteria:
inclusion criteria: 1. age 18-70 years old, no gender and race limited; 2. estimated life expectancy \> 12 weeks deemed by investigator； 3. cd22 were positive by histopathology and/or cytology diagnosis； 4. patients with relapsed and/or refractory non-hodgkin's b cell lymphoma (r/r b-nhl)； 5. relevant indicators for disease or assessment within 4 weeks after the last treatment; 6. quality of life score (kps) \>50%； 7. subject has adequate organ function at screening, cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by an echocardiogram (echo); serum alt/ ast \<3 upper limit of normal (uln); bilirubin\<2.0 mg/dl; serum creatinine ≤1.6 mg/dl and/or bun ≤ 1.5 mg/dl; 8. no remission or relapse after hematopoietic stem cell transplantation or autologous somatic immunotherapy; 9. unsuitable conditions for stem cell transplantation; 10. signed informed consent form (icf). exclusion criteria: 1. women in pregnancy or lactation; 2. in active infection including hepatitis b, hepatitis c, hiv, or other fatal viral and bacterial infection； 3. the absolute count of nonprimary neutrophil \< 0.75×10\^9/l or platelet count \< 50×10\^9/l; 4. abnormal vital signs and failure to cooperate with examination; 5. patients with mental or psychological diseases who cannot cooperate with treatment and efficacy evaluation; 6. highly allergic constitution or history of severe allergy; 7. patients with systemic infection or severe local infection requiring anti-infection treatment; 8. patients with severe autoimmune diseases; 9. presence of any other conditions that are unsuitable for this study as judged by the investigator.
cost free pharmacotherapy for smoking cessation in stroke patients

Conditions: Stroke

Summary: this pilot study examined the effect of providing a 4 weeks of cost free quit smoking medications to smokers identified in a stroke prevention clinic who were interested in quitting smoking compared to providing a prescription for the medication only.

design: randomized controlled trial. methods: all patients seen at the ottawa hospital stroke prevention clinic were screened for smoking status, advised to quit smoking and treated using a standardized protocol including counselling and pharmacotherapy. eligible smokers were randomly assigned to either a prescription only usual care group, or, the experimental group who received a 4-week supply of cost-free quit smoking medications and prescription for medication renewal. all patients received follow-up counselling 7-days prior to and 5, 14, 30, 60, 90, 180 days following their quit attempt. levels of eligibility, consent, adherence and retention were used as indicators of study feasibility. the primary outcome was bio-chemically validated quit rates at 26-weeks.

Eligibility criteria:
inclusion criteria: * patients were eligible to participate in the study if they reported smoking an average of 5 or more cigarettes per day in past 3 months; were 18 years of age or older; were willing to set a quit date in the next 30 days; and were willing to use a quit smoking medication. exclusion criteria: * patients who were unable to read and understand english or french or who had contraindications to all approved smoking cessation medications (nicotine replacement therapy, bupropion, and varenicline) were excluded from the study.

Keywords: stroke smoking cessation cost-free pharmacotherapy
analysis of the mechanisms of actions of heat shock protein (hsp27) responsible of the androgen-independent evolution in prostate cancer

Conditions: Androgen-independent Prostate Cancer

Summary: prostate cancer (pc) represents one of the most common cancers in industrialized countries. patients with localized disease may be treated with surgery or radiation, while androgen ablation is used as first-line therapy in patients with metastatic disease. while most patients initially respond well to this hormonal therapy, they most ultimately become unresponsive and recur within 2 years as androgen-independent prostate cancer (aipc). recently, docetaxel-based regimens have demonstrated improved survival in men with aipc in two different, large, phase iii studies. however, the median overall survival was prolonged for only 2 or 3 months. androgen independent (ai) progression involves variable combinations of clonal selection, adaptive up-regulation of anti-apoptotic genes, ligand-independent androgen receptor (ar) activation, alternative growth factor pathways, and immune system escape. additional therapeutic strategies targeting molecular mechanisms mediating resistance, combined with immunotherapy must be developed. one strategy to improve therapies in advanced pc involves targeting genes that are activated by androgen withdrawal, either to delay or prevent the emergence of the resistant ai phenotype. recently, a scientist,identified heat shock protein (hsp27) as a highly over-expressed gene in aipc. hsp27 knockdown using antisens oligonucleotides (aso) and small interfering rna (sirna) increased apoptotic rates and enhanced hormone- and chemo-therapy in pc. she developed and patented a 2nd generation aso targeting hsp27 that has been licensed (investigational drug called ogx-427) and clinical trials phase i/ii is currently in process in pc. despite ogx-427 efficiency, the functional role of stress induced hsp27 in castration or chemotherapy-induced apoptosis remains undefined. the purpose of this study is to elucidate the pathways leading to hsp27 action in androgen-independent prostate cancer in order to 1/ increase the pharmacological safety of ogx-427 and 2/find new specific therapeutic targets and treatment strategy for androgen-independent prostate cancer .


Eligibility criteria:
inclusion criteria: * prostate adenocarcinoma * patient \> 18 years old * patient affiliated to a social security system or benefiting from such a system * signed consent to participate exclusion criteria: * patient in emergency situation, major person being the object of a legal protective measure or unable to express its consent

Keywords: androgen-independent prostate cancer
a stepped-wedge cluster randomized controlled trial for evaluating an intervention in patients with stroke tailored education in addition to physiotherapist treatment

Conditions: Stroke

Summary: a stepped-wedge cluster design will be used, with the duration of the trial being 50 weeks. the 'stepped-wedge ' cluster randomised trial is a form of cross-over design with unidirectional cross-over ( from control to experimental ) but with randomisation of when each cluster undertakes this transition. in the stepped-wedge design, there is a staggered roll-out of the intervention, where the time and hence the sequence of units (clusters) that will start the intervention at each period is determined by random allocation. the randomisation occurs before the start of the trial. all clusters start the trial in a control phase with no intervention being delivered at any site, then sequentially cross over from the control group to the intervention group, until all sites are receiving the intervention. outcomes are measured on the study participants in all clusters at every time period, hence measurement of outcomes takes place at each step in the wedge; each cluster provides data points in the control and intervention conditions allowing each site to act as its own control.


Eligibility criteria:
inclusion criteria: * the study subjects were all patients who had been hospitalised in 8 regional hospitals of andalusian health service with acute cerebral stroke, clinically stable, presented an ischaemic or haemorrhagic aetiology and clinical symptoms of hemiplegia, were selectioned to receiving physiotherapy in hospitalisation, were assisted by a caregiver, had an adequate understanding of spanish, and had given their written informed consent.

Keywords: education physiotherapy
adipose tissue injection in perianal fistulas in crohn´s disease

Conditions: Crohn Disease; Perianal Fistulas; Cell- and Tissue-Based Therapy; Treatment

Summary: this randomized and placebo controlled study investigates the efficacy of injections with freshly harvested autologous adipose tissue in cd patients with complex perianal fistulas refractory to standard surgical and/or medical treatment. 140 cd patients will be included and randomized to either treatment with freshly harvested autologous adipose tissue or placebo (saline). primary outcome measures are clinical healing 6 months after treatment evaluated by clinical examination and pelvic mri.

injection with freshly harvested autologous adipose tissue has been reported to be an efficient treatment of perianal fistulas in patients with crohn´s disease (cd). in a prospective observational study 57 % of 21 patients with complex fistulas refractory to combined surgical and/or medical treatment achieved complete clinical healing of the treated fistulas from one to three injections. this randomized and placebo controlled study aims to confirm the efficacy of injections with freshly harvested autologous adipose tissue in cd patients with perianal fistulas. 140 cd patients with complex perianal fistulas refractory to standard surgical and/or medical treatment will be included and randomized to either treatment with freshly harvested autologous adipose tissue or placebo (saline). clinical evaluation of the treatment efficacy will also be performed in a blinded manner.

Eligibility criteria:
inclusion criteria: * diagnosed with crohn´s disease * perianal fistula with out branching or cavities with one external and one internal opening, which due to the risk for development of incontinence is not suitable for lay-open procedure, meaning: 1) all anterior interspinchteric and low transpinchteric (involving\ 1/3 of sphincter), suprasphincteric and ekstrasphincteric fistulas 4) intersphincteric or low transsphincteric fistula in patients with fecal incontinence and/or fecal urge. * no or minimal luminal disease activity by colonoscopy \< 3 months before treatment defined by simple endoscopic severity for crohn´s disease\<3 * prior optimal medical treatment for fistulas (immunmodulators, antibiotics and/or anti-tnf-alfa treatment) with out achieving fistula healing * treatment with seton for a minimum of 6 weeks * speaks and understand danish exclusion criteria: * pregnancy * changes in immunmodulator or anti-tnfalfa treatment \< 12 weeks * anovaginal fistulas * rectal or anal stenosis * active proctitis * stoma * previous surgery for fistulas besides simpel drainage or seton * smoker * insulin-dependent diabetes, conditions inducing defective immunity, pelvic radiation * pelvic mri contraindicated
effects of photobiomodulation on postoperative pain after primary endodontic therapy in molars with symptomatic apical periodontitis

Conditions: Postoperative Pain

Summary: the purpose of this study is to evaluate the effects of photobiomodulation (pbm) on postoperative pain after endodontic treatment in mandibular molar teeth diagnosed with symptomatic apical periodontitis.


Eligibility criteria:
inclusion criteria: * posterior mandibular molars * no previous root canal therapy on the tooth in question * able to complete the endodontic treatment in one visit exclusion criteria: * maxillary teeth, mandibular anteriors and premolars * infection (swelling, sinus tract) on the tooth in question * periodontal disease on the tooth in question * dental trauma * crown/ root fractures * systemic diseases * immunocompromised patients

Keywords: endodontic treatment mandibular molar teeth apical periodontitis.
performance of fanfilcon a toric lenses after at least one month wearing enfilcon a toric lenses

Conditions: Astigmatism

Summary: this is a prospective, multi-center, subject-masked, bilateral, daily wear, two-month dispensing study

the aim of this study is to determine if adapted contact lens wearers enfilcon a toric lenses can be confidently refit into fanfilcon a toric lenses and can be successful after one month of daily wear.

Eligibility criteria:
inclusion criteria: a person is eligible for inclusion in the study if he/she: * is between 18 and 40 years of age (inclusive) * has had a self-reported eye exam in the last two years * is a habitual soft toric lens wearer * can be successfully fit with study lenses (≥ grade 2 fit acceptance) * has a contact lens spherical prescription between -1.00 to -6.00d with a cylinder between -0.75 and -1.75d (diopters) (inclusive) * has a spectacle cylinder of at least 0.75d in each eye. * can achieve best corrected spectacle refraction distance visual acuity of 20/25 (0.10 logmar) or better in each eye. * can achieve a distance visual acuity of 20/30 (0.18 logmar) or better in each eye with the study contact lenses. * has clear corneas and no active ocular disease * has read, understood and signed the information consent letter * has a contact lens refraction that fits within the available parameters of the study lenses * is willing to comply with the wear schedule (at least 5 days per week, \> 8 hours/day assuming there are no contraindications for doing so) * is willing to comply with the visit schedule. exclusion criteria: a person will be excluded from the study if he/she: * has a history of not achieving comfortable cl (contact lens) wear (5 days per week; \> 8 hours/day) * presents with clinically significant anterior segment abnormalities * presents with ocular or systemic disease or need of medications which might interfere with contact lens wear * presents with slit lamp findings that would contraindicate contact lens wear such as: * pathological dry eye or associated findings * significant pterygium, pinguecula, or corneal scars within the visual axis * neovascularization \> 0.75 mm in from of the limbus * anterior uveitis or iritis (or history in past year) * seborrheic eczema of eyelid region, seborrheic conjunctivitis * history of corneal ulcers or fungal infections * poor personal hygiene * has a known history of corneal hypoesthesia (reduced corneal sensitivity) * has aphakia, keratoconus or a highly irregular cornea. * has presbyopia or has dependence on spectacles for near work over the contact lenses. * has undergone corneal refractive surgery. * is participating in any other type of eye related clinical or research study. * is frequently using rewetting/ lubricating eye drops (more than once per day)
impairment of reading ability in dry eye patients

Conditions: Dry Eye Syndromes

Summary: to assess the reading function impairment in patients with dry eye and to assess the effects of reading on the ocular surface.

this study is being done to understand how reading is affected in people with dry eye in comparison with healthy controls and what effect reading has on the ocular surface in patients with dry eye.

Eligibility criteria:
inclusion criteria: * age of 50 or greater, * literacy in english language, * ability to give informed consent exclusion criteria: * binocular vision below 20/25, * any ocular surgery within the last 3 months, * mental issues, * illiteracy, * language problems which might possibly interfere with reading ability, * history of taking or current use of topical prescription anti-inflammatory eye drops (including, cyclosporine and steroids as well as any glaucoma eye drops).
transoral endoscopic liver biopsy during laparoscopic gastric bypass

Conditions: Steatohepatitis; Morbid Obesity

Summary: this research is being done to evaluate the ability to obtain a liver sample using upper endoscopy rather than through a laparoscopic procedure. the investigators hypothesize that the endoscopic transoral route is as effective as the laparoscopic route.


Eligibility criteria:
inclusion criteria: 1. any patient who meets criteria to undergo laparoscopic roux-en y gastric bypass (bmi\>40 or bmi\>35 with multiple medical co morbidities). 2. age greater than 18 years. 3. ability to complete all necessary components of study (gastric bypass surgery standard qualifications). exclusion criteria: 1. inability to give informed consent 2. women who are pregnant or in whom pregnancy status cannot be confirmed.

Keywords: transoral transluminal endoscopic laparoscopic liver biopsy
trial comparing 19 and 25-gauge eus-fna needles

Conditions: Cancer of Pancreas; Pancreatic Neoplasm

Summary: this study compares the 19g and 25g needles for procuring tissue samples from the pancreas during endoscopic ultrasound (eus) procedures.

the study compares the median number of passes to establish a definitive diagnosis using the 19g or 25g needles. also, the ability of both needles to procure a histological core tissue is assessed.

Eligibility criteria:
inclusion criteria: (1) patients with solid pancreatic mass lesions. exclusion criteria: 1. age \< 19 years 2. unable to safely undergo eus for any reason 3. coagulopathy (inr \> 1.6, prothrombin time \> 18secs, thrombocytopenia \< 80,000 cells/ml) 4. unable to consent 5. non-english speaking patients